dalteparin has been researched along with Lymphoma, Non-Hodgkin in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrahim, RB | 1 |
| Stroempl, LE | 1 |
| Abella, EM | 1 |
| Racine, E | 1 |
1 other study available for dalteparin and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Enoxaparin safety in patients with severe thrombocytopenia.
Topics: Anticoagulants; Bone Marrow Transplantation; Enoxaparin; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 2002 |